Bibliography
- Aragon-Ching JB , LiH, GardnerER, FiggWD: Thalidomide analogues as anticancer drugs.Recent Pat. Anticancer Drug Discov.2, 167–174 (2007).
- Melchert M , ListA: The thalidomide saga.Int. J. Biochem. Cell Biol.39, 1489–1499 (2007).
- Bartlett JB , DredgeK, DalgleishAG: The evolution of thalidomide and its IMiD derivatives as anticancer agents.Nat. Rev. Cancer4, 314–322 (2004).
- Richardson PG , BloodE, MitsiadesCSet al.: A randomized Phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.Blood108, 3458–3464 (2006).
- Richardson P , JagannathS, HusseinMet al.: Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.Blood114, 772–778 (2009).
- Weber DM , ChenC, NiesvizkyRet al.: Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.N. Engl. J. Med.357, 2133–2142 (2007).
- Dimopoulos M , SpencerA, AttalMet al.: Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.N. Engl. J. Med.357, 2123–2132 (2007).
- Galustian C , DalgleishA: Lenalidomide: a novel anticancer drug with multiple modalities.Expert Opin. Pharmacother.10, 125–133 (2009).
- Van Etten RA , ShannonKM: Focus on myeloproliferative diseases and myelodysplastic syndromes.Cancer Cell6, 547–552 (2004).
- List A , DewaldG, BennettJet al.: Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.N. Engl. J. Med.355, 1456–1465 (2006).
- Ortega J , ListA: Immunomodulatory drugs in the treatment of myelodysplastic syndromes.Curr. Opin. Oncol.19, 656–659 (2007).
- Sokol L , ListAF: Immunomodulatory therapy for myelodysplastic syndromes.Int. J. Hematol.86, 301–305 (2007).
- Ades L , BoehrerS, PrebetTet al.: Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a Phase 2 study.Blood113, 3947–3952 (2009).
- Ferrajoli A , LeeBN, SchletteEJet al.: Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.Blood111, 5291–5297 (2008).
- Ramsay AG , JohnsonAJ, LeeAMet al.: Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.J. Clin. Invest.118, 2427–2437 (2008).
- James DF , BettyMR, MosadeghiR, KippsTJ: Lenalidomide abrogates the protective influence of nurse-like cells on primary chronic lymphocytic leukemia cells in vitro.Blood110, A916–A917 (2007).
- Wildes TM , BartlettNL: Drug development for recurrent and refractory classical Hodgkin lymphoma.Leuk. Lymphoma50, 529–540 (2009).
- Witzig TE , WiernikPH, MooreTet al.: Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin’s Lymphoma.J. Clin. Oncol.27, 5404–5409 (2009).
- Habermann TM , LossosIS, JusticeGet al.: Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.Br. J. Haematol.145, 344–349 (2009).
- Lapalombella R , YuB, TriantafillouGet al.: Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.Blood112, 5180–5189 (2008).
- Lapalombella R , GowdaA, JoshiTet al.: The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia.Br. J. Haematol.144, 848–855 (2009).
- Awan FT , LapalombellaR, TrottaRet al.: CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.Blood115, 1204–1213 (2010).
- Bartlett JB , MichaelA, ClarkeIAet al.: Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers.Br. J. Cancer90, 955–961 (2004).
- Dredge K , MarriottJB, TodrykSMet al.: Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity.J. Immunol.168, 4914–4919 (2002).
- Rajkumar SV , JacobusS, CallanderNet al.: Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group: analysis of response, survival, and outcome wi.J. Clin. Oncol.26(Suppl.), Abstract 8504 (2008).
- Liu W , NizarS, DalgleishA: Gemcitabine and lenalidomide combination in a patient with metastatic pancreatic cancer: a case study.Med. Oncol.27, 430–433 (2010).
- Galustian C , MeyerB, LabartheMCet al.: The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.Cancer Immunol. Immunother.58, 1033–1045 (2009).
- Henry JY , LuL, AdamsMet al.: Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo. Presented at: 101st Annual Meeting of the American Association for Cancer Research. Washington, DC, USA, 17–21 April 2010.
- Ning YM , GulleyJL, ArlenPMet al.: Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.J. Clin. Oncol.28, 2070–2076 (2010).
- Mathew P , TannirN, TuSM, CarterCM, BekeleNB, PagliaroL: A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy.Cancer Chemother. Pharmacol.65, 811–815 (2010).
- Petrylak DP , Resto-GarcesK, TibyanM, MohileSG: A Phase I open-label study using lenalidomide and docetaxel in castration- resistant prostate cancer.J. Clin. Oncol.27(Suppl.), Abstr. 5156 (2009).
- Nabhan C , TolzienK, KelbyK, LestingiTM: Lenalidomide (Revlimid®) has single agent activity in chemotherapy-naïve castration-resistant prostate cancer (CRPC). Presented at: 2010 Genitourinary Cancers Symposium. San Francisco, CA, USA, 5–7 March 2010.
- Sinibaldi VJ , CarducciMA, Moore-CooperSet al.: A randomized double blind Phase I–II study to determine the tolerability/efficacy of two different doses of lenalidomide (L), CC- 5013, in biochemically relapsed (BR) prostate cancer (PC) patients (pts) (M0) after local treatment (LT).J. Clin. Oncol.27(Suppl.), Abstr. 5130 (2009).
- Brosseau C , ColstonK, DalgleishAG, GalustianC: The immunomodulatory drug lenalidomide restores a vitamin D sensitive phenotype to the vitamin D resistant breast cancer cell line MDA-MB-231. Presented at:101st Annual Meeting of the American Association for Cancer Research Washington, DC, USA, 17–21 April 2010.
- Liu WM , FowlerDW, SmithP, DalgleishAG: Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses.Br. J Cancer102, 115–123 (2010).
- Blansfield JA , CaragacianuD, AlexanderHRIIIet al.: Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy.Clin. Cancer Res.14, 270–280 (2008).
- Dalgleish AG , O’ByrneK: Inflammation and cancer: the role of the immune response and angiogenesis.Cancer Treat. Res.130, 1–38 (2006).
- Marriott JB , ClarkeIA, DredgeK, MullerG, StirlingD, DalgleishAG: Thalidomide and its analogues have distinct and opposing effects on TNF-α and TNFR2 during co-stimulation of both CD4+ and CD8+ T cells.Clin. Exp. Immunol.130, 75–84 (2002).
- Noonan KA , FergusonA, EmerlingAet al.: Lenalidomide augments immune responses to prevnar vaccination in relapsed myeloma patients: implications for cancer and infectious vaccines.ASH Annual Meeting Abstracts114, 1864 (2009).
- Schey SA , FieldsP, BartlettJBet al.: Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.J. Clin. Oncol.22, 3269–3276 (2004).
- Kran AM , SorensenB, SommerfeltMA, NyhusJ, BaksaasI, KvaleD: Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cells.AIDS20, 627–630 (2006).
- Cadogan M , AustenB, HeeneyJL, DalgleishAG: HLA homology within the C5 domain promotes peptide binding by HIV type 1 gp120.AIDS Res. Hum. Retroviruses24, 845–855 (2008).
- Cadogan M , DalgleishAG: Pathogenesis of HIV: non-specific immune hyperactivity and its implications for vaccines.Clin. Med.8, 267–271 (2008).
- Cadogan M , DalgleishAG: HIV immunopathogenesis and strategies for intervention.Lancet Infect. Dis.8, 675–684 (2008).
- Cadogan M , DalgleishAG: HIV induced AIDS and related cancers: chronic immune activation and future therapeutic strategies.Adv. Cancer Res.101, 349–395 (2008).
- Maraveyas A , BabanB, KennardDet al.: Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes.Ann. Oncol.10, 817–824 (1999).
- Dlugovitzky D , BottassoO, DomininoJCet al.: Clinical and serological studies of tuberculosis patients in Argentina receiving immunotherapy with Mycobacterium vaccae (SRL 172).Respir. Med.93, 557–562 (1999).
- O’Brien ME , SainiA, SmithIEet al.: A randomized Phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma.Br. J Cancer83, 853–857 (2000).
- Assersohn L , SouberbielleBE, O’BrienMEet al.: A randomized pilot study of SRL172 (Mycobacterium vaccae) in patients with small cell lung cancer (SCLC) treated with chemotherapy.Clin. Oncol. (R. Coll. Radiol.)14, 23–27 (2002).
- Mwinga A , NunnA, NgwiraBet al.: Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial.Lancet360, 1050–1055 (2002).